^
Association details:
| Biomarker: | FGFR2 amplification |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | zoligratinib (Debio 1347) (FGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Published date:
05/01/2019
Excerpt:
Overall, a decrease in DUSP6 was observed on treatment; 2 of 3 patients with a decrease >50% achieved a PR on treatment Table 4; Supplementary Table S9).
DOI:
10.1158/1078-0432.CCR-18-1959
